Anti-CD40 antibodies
The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
1. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
a) a heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO: 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17; and
b) the light chain CDR1 sequence has a sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:22 through SEQ ID NO:23, and a light chain CDR3 sequence selected from the group consisting of SEQ ID NO:24 through SEQ ID NO:25.
2. The antibody of claim 1 , wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 10, a heavy chain CDR2 sequence of SEQ ID NO:13 and a heavy chain CDR3 sequence of SEQ ID NO:16; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:19, a light chain CDR2 sequence of SEQ ID NO:22 and a light chain CDR3 sequence of SEQ ID NO:24.
3. The antibody of claim 1 , wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 9, a heavy chain CDR2 sequence of SEQ ID NO:14 and a heavy chain CDR3 sequence of SEQ ID NO:16; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:20, a light chain CDR2 sequence of SEQ ID NO:22 and a light chain CDR3 sequence of SEQ ID NO:24.
4. The antibody of claim 1 , wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 11, a heavy chain CDR2 sequence of SEQ ID NO:15 and a heavy chain CDR3 sequence of SEQ ID NO:17; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:23 and a light chain CDR3 sequence of SEQ ID NO:25.
5. A humanized monoclonal antibody or antibody fragment that specifically binds to human CD40, having a heavy chain variable domain and a light chain variable region comprising the amino acid sequences of SEQ ID NO:27 and SEQ ID NO:26, respectively; SEQ ID NO:28 and SEQ ID NO:26, respectively; SEQ ID NO:29 and SEQ ID NO:26, respectively; SEQ ID NO:30 and SEQ ID NO:26, respectively; SEQ ID NO:32 and SEQ ID NO:31, respectively; SEQ ID NO:33 and SEQ ID NO:31, respectively; SEQ ID NO:34 and SEQ ID NO:31, respectively; SEQ ID NO:35 and SEQ ID NO:31, respectively; SEQ ID NO:37 and SEQ ID NO:36, respectively; SEQ ID NO:38 and SEQ ID NO:36, respectively; SEQ ID NO:39 and SEQ ID NO:36, respectively; SEQ ID NO:40 and SEQ ID NO: 36, respectively.
6. A method of inhibiting the activation of human CD40 in a human patient comprising administering to said human patient a composition comprising an antibody of claim 1 in an amount sufficient to inhibit the activation of human CD40 in said human patient.
7. A method of treating or ameliorating a disease or disorder in a human patient by inhibiting the activation of human CD40, comprising administering to said human patient a composition comprising an antibody of claim 1 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the human patient.
8. The method of claim 7 , wherein the disease or disorder is selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-expressing cancer.
9. A method of treating an autoimmune or inflammatory disease or disorder by inhibiting the activation of human CD40, the method comprising administering to a human patient in need thereof a composition comprising an antibody of claim 1 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the human patient, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis, Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis.
10. The method of claim 7 , further comprising administering a second therapeutic agent selected from the group consisting of a cytostatic agent, a cytotoxic agent, or an immunosuppressive agent.
11. The method of claim 7 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
12. A pharmaceutical composition comprising: (i) the antibody of claim 1 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.
13. A method of treating or ameliorating rheumatoid arthritis in a mammal comprising administering to said mammal a composition comprising an antibody of claim 1 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
14. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 11, a heavy chain CDR2sequence of SEQ ID NO:15 and a heavy chain CDR3 sequence of SEQ ID NO:17; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:23 and a light chain CDR3 sequence of SEQ ID NO:25.
15. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 9, a heavy chain CDR2sequence of SEQ ID NO:12 and a heavy chain CDR3 sequence of SEQ ID NO:16; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:18, a light chain CDR2sequence of SEQ ID NO:22 and a light chain CDR3 sequence of SEQ ID NO:24.
16. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain variable region of SEQ ID NO: 44 and a light chain variable region of SEQ ID NO: 43.
17. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain variable region of SEQ ID NO: 53 and a light chain variable region of SEQ ID NO: 52.
18. A humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain variable region of SEQ ID NO: 58 and a light chain variable region of SEQ ID NO: 56.
19. A humanized monoclonal antibody or antibody fragment that specifically binds to human CD40, comprising a heavy chain of SEQ ID NO:30 and a light chain of SEQ ID NO:26.
20. A humanized monoclonal antibody or antibody fragment that specifically binds to human CD40, comprising a heavy chain of SEQ ID NO:35 and a light chain of SEQ ID NO:31.
21. A humanized monoclonal antibody or antibody fragment that specifically binds to human CD40, comprising a heavy chain of SEQ ID NO:40 and a light chain of SEQ ID NO:36.
22. A method of treating or ameliorating an autoimmune or inflammatory disease or disorder in a human patient by inhibiting the activation of human CD40, the method comprising administering to the human patient a composition comprising an antibody of claim 14 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the human patient, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis, Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis.
23. The method of claim 22 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
24. A method of treating or ameliorating an autoimmune or inflammatory disease or disorder in a human patient by inhibiting the activation of human CD40, the method comprising administering to the human patient a composition comprising an antibody of claim 15 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the human patient, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis, Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis.
25. The method of claim 24 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
26. A method of treating or ameliorating rheumatoid arthritis in a mammal comprising administering to said mammal a composition comprising an antibody of claim 19 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
27. The method of claim 26 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
28. A method of treating or ameliorating rheumatoid arthritis in a mammal comprising administering to said mammal a composition comprising an antibody of claim 20 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
29. The method of claim 28 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
30. A method of treating or ameliorating rheumatoid arthritis in a mammal comprising administering to said mammal a composition comprising an antibody of claim 21 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
31. The method of claim 30 , wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.
32. A method of treating or ameliorating systemic lupus erythematosus (SLE) in a mammal comprising administering to said mammal a composition comprising an antibody of claim 19 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
33. The method of claim 32 , wherein said mammal is a human patient.
34. A method of treating or ameliorating systemic lupus erythematosus (SLE) in a mammal comprising administering to said mammal a composition comprising an antibody of claim 20 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
35. The method of claim 34 , wherein said mammal is a human patient.
36. A method of treating or ameliorating systemic lupus erythematosus (SLE) in a mammal comprising administering to said mammal a composition comprising an antibody of claim 21 in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.
37. The method of claim 36 , wherein said mammal is a human patient.
38. A pharmaceutical composition comprising: (i) the antibody of claim 19 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.
39. A pharmaceutical composition comprising: (i) the antibody of claim 20 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.
40. A pharmaceutical composition comprising: (i) the antibody of claim 21 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.
41. A pharmaceutical composition comprising: (i) the antibody of claim 14 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.
42. A pharmaceutical composition comprising: (i) the antibody of claim 15 ; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.